FDA De Novo Classification Strategy

by Dr. Ebot Eyong, PhD, CQE, RAC.

Executive Summary

Medical innovation often advances faster than regulatory precedent. While the FDA’s 510(k) pathway provides an efficient route to market for devices that can demonstrate substantial equivalence to an existing legally marketed product, truly novel technologies frequently face a different challenge: there is no appropriate predicate device.

This was the situation faced by a rapidly growing digital health company that had developed an artificial intelligence–enabled clinical decision support platform designed to assist healthcare professionals in interpreting complex physiological data. Technology incorporated machine learning algorithms, cloud-based analytics, and an intuitive user interface to support clinical workflows. Although early evaluations demonstrated promising performance and strong clinician acceptance, the regulatory pathway remained uncertain.

The company’s leadership initially hoped to pursue a Traditional 510(k). However, after preliminary regulatory research, it became apparent that no legally marketed predicate device possessed the same intended use and technological characteristics. Attempting to force the technology into an unsuitable 510(k) framework risked a Not Substantially Equivalent (NSE) determination, unnecessary delays, and increased development costs.

Recognizing the need for an experienced regulatory partner, the company engaged E&E Medicals to evaluate available FDA pathways, develop a comprehensive De Novo strategy, coordinate interactions with FDA reviewers, and establish the scientific foundation necessary to support the first marketing authorization for this new category of medical technology.

Company Background

The client was an innovative healthcare technology company founded by physicians, biomedical engineers, software architects, and data scientists. Its mission was to leverage artificial intelligence to improve the efficiency and consistency of clinical decision-making while preserving physician oversight.

The platform integrated multiple sources of patient information — including physiological measurements, laboratory data, and historical trends — to generate structured analyses intended to support healthcare professionals during routine clinical evaluations. Importantly, the system was designed to assist clinicians rather than replace medical judgment, with all recommendations subject to independent professional review.

The company’s technology represented years of investment in algorithm development, software engineering, cybersecurity, human-centered design, and clinical collaboration. Venture capital funding had accelerated product development, and investor expectations centered on achieving U.S. commercialization within an aggressive timeline.

Despite the technical sophistication of the product, leadership understood that regulatory success would ultimately determine whether the technology could reach healthcare providers and patients.

The Initial Challenge

At the outset of the engagement, the client faced a familiar dilemma encountered by many innovators introducing first-of-their-kind medical technologies.

The engineering team successfully demonstrated algorithm performance through internal testing and retrospective analyses. User interface development had progressed rapidly, cybersecurity architecture had been designed using recognized industry frameworks, and software verification activities were well underway. However, regulatory planning had not advanced at the same pace.

Management conducted preliminary searches of FDA’s public databases and identified several AI-related medical devices with seemingly comparable capabilities. A deeper analysis performed by E&E Medicals revealed important distinctions. Although some products used artificial intelligence or software analytics, their intended uses, clinical indications, target populations, and technological characteristics differed substantially from the client’s product.

Without an appropriate predicate device, a Traditional 510(k) would likely fail because the FDA could conclude that the product raised different questions of safety and effectiveness.

The company needed clarity before committing millions of dollars to additional verification testing and clinical studies.

Regulatory Assessment

Press enter or click to view image in full size

E&E Medicals and Consulting initiated the project with a comprehensive regulatory assessment designed to answer one fundamental question: Which FDA pathway offered the greatest likelihood of successful commercialization?

The assessment examined the product from multiple perspectives, including:

· Intended use and indications for use

· Product functionality

· Software architecture

· Machine learning methodology

· Clinical workflow integration

· Risk profile

· Existing FDA product codes

· Historical De Novo decisions

· Relevant guidance documents

· Consensus standards

· Similar marketed technologies

· International regulatory classifications

Rather than focusing solely on technical similarities, E&E Medicals evaluated whether existing products addressed the same clinical questions and whether their technological differences could introduce new issues of safety or effectiveness.

The analysis confirmed that no legally marketed predicate could support a scientifically defensible claim of substantial equivalence.

Why the De Novo Pathway Was Appropriate

The conclusion that no suitable predicate existed did not represent a setback. Instead, it created an opportunity.

The FDA’s De Novo pathway was specifically established for novel devices that present low to moderate risk but lack an appropriate predicate. Successful De Novo classification not only authorizes marketing of the new device but also establishes a new device classification that may serve as a predicate for future technologies.

E&E Medicals explained to executive leadership that the De Novo pathway would allow the company to present the product on its own scientific merits rather than attempting to compare it to technologies that were fundamentally different.

This strategic shift also aligned with the company’s long-term business objectives by positioning it as an innovator capable of defining a new category within digital health.

Establishing the Regulatory Vision

Once the De Novo pathway had been selected, E&E Medicals worked with company leadership to establish a long-term regulatory vision extending beyond initial authorization.

The objective was not simply to obtain FDA marketing authorization but to build a regulatory framework capable of supporting future software updates, expanded indications, international market access, and continued product evolution.

A Regulatory Master Plan was developed that integrated:

· Software development milestones

· Clinical evidence generation

· Risk management

· Quality management system implementation

· FDA interactions

· Cybersecurity planning

· Human factors engineering

· Post-market surveillance strategy

· Commercialization planning

This roadmap provided leadership with a clear sequence of activities and decision points, allowing technical, clinical, quality, and commercial teams to work toward common objectives.

Early Engagement with FDA

Recognizing the importance of obtaining regulatory feedback before finalizing development activities, E&E Medicals recommended participation in the FDA’s Q-Submission Program.

A detailed pre-submission package was prepared, describing the technology, proposed intended use, software architecture, machine learning methodology, risk analysis, planned verification testing, anticipated clinical evidence, and specific questions requiring FDA feedback.

The pre-submission meeting proved invaluable.

FDA reviewers provided constructive comments regarding the proposed indications for use, recommended refinements to the clinical evaluation strategy, emphasized expectations for software documentation, and discussed appropriate approaches for validating algorithm performance across representative patient populations.

Receiving this feedback early allowed the client to optimize development activities before committing significant additional resources.

Addressing Artificial Intelligence Considerations

Artificial intelligence introduces unique regulatory considerations beyond those encountered in traditional software.

eeMeds™ worked closely with software engineers and data scientists to establish documentation supporting transparency, repeatability, and performance consistency.

Algorithm development processes were documented from initial concept through model selection, training, testing, validation, and deployment.

Special attention was given to:

· Data quality

· Dataset representativeness

· Bias evaluation

· Performance consistency

· False positive and false negative analysis

· Version control

· Change management

· Software lifecycle documentation

· Cybersecurity protections

· Human oversight mechanisms

Although the software incorporated machine learning techniques, E&E Medicals ensured that clinical users remained responsible for final medical decisions, reinforcing the system’s role as a decision-support tool.

Clinical Evidence Development

Because no predicate existed, robust clinical evidence became especially important.

E&E Medicals collaborated with physicians, statisticians, software developers, and clinical operations specialists to develop an evidence-generation strategy capable of demonstrating both safety and effectiveness.

Clinical evaluations were designed to answer practical regulatory questions rather than simply demonstrate technical performance.

Investigators evaluated:

· Algorithm accuracy

· Clinical usability

· Workflow integration

· User comprehension

· Diagnostic consistency

· Clinical efficiency

· Safety monitoring

· Human factors

· Real-world usability

Study endpoints were selected to provide meaningful evidence supporting the proposed intended use while avoiding unnecessary complexity.

Risk Management

Risk management activities extended throughout the software development lifecycle.

Potential hazards included:

· Incorrect algorithm output

· User misunderstanding

· Cybersecurity threats

· Data integrity failures

· System downtime

· Incomplete data inputs

· Interface design errors

· Integration failures

· Cloud infrastructure interruptions

Each hazard underwent systematic evaluation using ISO 14971 principles.

Where risks could not be eliminated entirely, multiple layers of mitigation were implemented through software controls, user interface improvements, clinician training, validation testing, labeling, and ongoing monitoring.

This comprehensive approach demonstrated that foreseeable risks had been reduced as far as reasonably practicable.

Preparing the De Novo Submission

Developing the De Novo application required more than compiling technical reports.

E&E Medicals structured the submission as a coherent scientific narrative demonstrating why the device represented a reasonable assurance of safety and effectiveness despite the absence of a predicate.

Each section of the submission built upon the previous one.

The device description established technological context.

Risk analyses demonstrated systematic hazard management.

Verification reports confirmed technical performance.

Clinical evidence supported intended use.

Software documentation established lifecycle control.

Cybersecurity documentation demonstrated protection of patient information and system integrity.

Quality system documentation reinforced organizational maturity.

Rather than overwhelming reviewers with excessive data, the submission emphasized scientific clarity, logical organization, and transparent decision-making.

Establishing a New Regulatory Category

One of the most significant achievements of the engagement was positioning the client’s technology to establish a new FDA device classification.

Successful De Novo authorization would allow future manufacturers developing substantially equivalent technologies to pursue the 510(k) pathway using the newly classified device as a predicate.

This outcome not only benefited the client but also contributed to the broader evolution of medical technology regulation.

Outcome

By the conclusion of the engagement, the company possessed a comprehensive regulatory strategy supported by a mature quality management system, well-defined software lifecycle documentation, robust clinical evidence planning, integrated risk management, and a scientifically defensible De Novo submission.

Perhaps most importantly, executive leadership gained confidence that commercialization decisions were being driven by sound regulatory science rather than assumptions or incomplete information.

The engagement transformed regulatory affairs from a perceived compliance function into a strategic business capability supporting innovation, investment, and long-term growth.

Business Impact

The benefits extended well beyond regulatory planning.

Engineering teams gained clearer development priorities. Clinical investigators conducted studies aligned with FDA expectations. Investors viewed the strengthened regulatory strategy as evidence of organizational maturity. Product managers were able to develop commercialization plans with greater confidence, while quality personnel implemented processes capable of supporting future software releases and product expansions.

Most significantly, the company established itself as a pioneer within its emerging technology category, creating opportunities for future product development and market leadership.

Why E&E Medicals Was Chosen

Developing a first-of-its-kind medical technology requires more than technical excellence — it demands a regulatory strategy capable of transforming innovation into an approvable product.

E&E Medicals provided strategic leadership by integrating FDA regulatory science, software quality, clinical evidence generation, risk management, and business planning into a unified commercialization program.

Through careful pathway selection, proactive FDA engagement, rigorous documentation, and disciplined project management, E&E Medicals helped the client to introduce a novel medical technology while establishing the regulatory foundation for future innovation.

His professional website provides a central overview of his work, while dedicated sections for ventures, projects, and professional publications provide additional insight into his professional interests and activities.

Learn More About Dr. Ebot Eyong and E&E Medicals

To explore his professional work, visit Dr. Ebot Eyong’s official website and learn more about E&E Medicals and Consulting.

You can also explore the company’s healthcare and regulatory ecosystem through eeMeds™, E&E Medical Supply, and the company’s wider professional resources